REPLICATE BIOSCIENCE

replicate-bioscience-logo

Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

#SimilarOrganizations #People #Financial #Event #Website #More

REPLICATE BIOSCIENCE

Social Links:

Industry:
Biotechnology Health Care Life Science Therapeutics

Founded:
2020-01-01

Address:
San Diego, California, United States

Country:
United States

Website Url:
http://www.replicatebioscience.com

Total Employee:
11+

Status:
Active

Email Addresses:
info@replicatebioscience.com

Total Funding:
46 M USD


Similar Organizations

acrivon-therapeutics-logo

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

aulos-bioscience-logo

Aulos Bioscience

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

autobahn-therapeutics-logo

Autobahn Therapeutics

Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.

creyon-bio-logo

Creyon Bio

Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

not_available_image

Foresight Diagnostics

Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw.

cultured-decadence-logo

Cultured Decadence

Cultured Decadence creats novel methods to make crustacean products using cell culture and tissue engineering techniques.

mercy-bioanalytics-logo

Mercy BioAnalytics

Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.

nurix-therapeutics-logo

Nurix Therapeutics

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

ocelot-bio-logo

Ocelot Bio

Ocelot Bio brings new treatment options to patients with severe liver disease.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.


Current Advisors List

joseph-a-yanchik-iii_image

Joseph A. Yanchik III Board Member @ Replicate Bioscience
Board_member
2021-09-01

seth-harrison_image

Seth Harrison Board Member @ Replicate Bioscience
Board_member
2021-09-01

mohit-trikha_image

Mohit Trikha Board Member @ Replicate Bioscience
Board_member
2022-06-01

Current Employees Featured

nathaniel-wang_image

Nathaniel Wang
Nathaniel Wang CEO/CSO and Co-Founder @ Replicate Bioscience
CEO/CSO and Co-Founder

herbert-kim-lyerly_image

Herbert Kim Lyerly
Herbert Kim Lyerly Co-Founder @ Replicate Bioscience
Co-Founder
2020-06-01

zachary-hartman_image

Zachary Hartman
Zachary Hartman Co-Founder @ Replicate Bioscience
Co-Founder

not_available_image

Zelanna Goldberg
Zelanna Goldberg Chief Medical Officer @ Replicate Bioscience
Chief Medical Officer
2022-01-01

andrew-geall_image

Andrew Geall
Andrew Geall CDO and Co-Founder @ Replicate Bioscience
CDO and Co-Founder

Founder


andrew-geall_image

Andrew Geall

herbert-kim-lyerly_image

Herbert Kim Lyerly

nathaniel-wang_image

Nathaniel Wang

zachary-hartman_image

Zachary Hartman

Investors List

apple-tree-partners_image

Apple Tree Partners

Apple Tree Partners investment in Series A - Replicate Bioscience

apple-tree-partners_image

Apple Tree Partners

Apple Tree Partners investment in Seed Round - Replicate Bioscience

Official Site Inspections

http://www.replicatebioscience.com

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Replicate Bioscience"

Replicate Bioscience - Crunchbase Company Profile

Contact Email info@replicatebioscience.com Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self …See details»

About Us | Replicate Bioscience

Guided by our team of srRNA experts and with a customizable library of synthetic srRNA vectors and end-to-end development capabilities at our disposal, we are uniquely positioned to …See details»

Replicate Bioscience 2025 Company Profile: Valuation, …

Information on valuation, funding, cap tables, investors, and executives for Replicate Bioscience. Use the PitchBook Platform to explore the full profile.See details»

Replicate Bioscience, Inc. | LinkedIn

Replicate Bioscience, Inc. | 2,862 followers on LinkedIn. The Power of RNA Amplified | Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA ...See details»

Replicate Bioscience, Inc. Information - RocketReach

Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two …See details»

Replicate Bioscience, Inc. - Drug pipelines, Patents, Clinical trials ...

Mar 7, 2025 replicatebioscience.com. Startups | Holding Company | 2020 | California, United States | 10-50 | replicatebioscience.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. …See details»

Replicate Bioscience - Overview, News & Similar companies

Apr 22, 2024 View Replicate Bioscience (www.replicatebioscience.com) location in California, United States , revenue, industry and description. Find related and similar companies as well …See details»

Replicate Bioscience - Company Profile - Tracxn

Feb 24, 2025 Replicate Bioscience - Developer of RNA-Based therapeutics for cancer treatment. Raised a total funding of $46M over 2 rounds from 1 investor. Founded by Nathaniel Wang …See details»

Replicate Bioscience - VentureRadar

"Replicate harnesses the body’s natural protein-making power and uses synthetic biology to design unique self-replicating RNAs (srRNAs) that can direct that power to fight disease.See details»

Curia and Replicate Bioscience Enter Strategic

Jun 9, 2022 For more information, visit www.replicatebioscience.com. Contacts Curia Corporate Contact: Sue Zaranek Curia +1 518 512 2111 corporatecommunications@CuriaGlobal.comSee details»

Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation ...

SAN DIEGO, Calif., Sept. 12, 2023 – Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA …See details»

Curia and Replicate Bioscience Enter Strategic ... - Curia Global

ALBANY, N.Y.–(BUSINESS WIRE)–Curia a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent …See details»

Replicate Bioscience Announces Positive Initial Clinical Results for ...

Feb 14, 2024 Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today …See details»

Replicate Bioscience Announces Publication of First-in-Human …

Feb 7, 2025 Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000’s potential to offer a meaningful …See details»

Replicate Bioscience – 2021 OTC Annual Report

Oct 20, 2021 NEW YORK and SAN DIEGO, Sept. 8, 2021 /PRNewswire/ — ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company …See details»

Replicate Bioscience Announces Publication of First-in-Human …

Feb 7, 2025 The Phase I study showed that a single dose of RBI-4000 elicited immune responses that attained a World Health Organization (WHO)-established immune threshold of …See details»

Dosing the first person with srRNA: Advancing a novel technology ...

Sep 28, 2023 Replicate recently announced initiation of a Phase 1 trial of RBI-4000, a self-replicating RNA (srRNA) vaccine developed to protect humans against the rabies virus. Learn …See details»

Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation ...

SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of …See details»

Establishing Canada’s first large-scale bioinnovation centre

1 day ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»

Replicate Bioscience Initiates a Phase 1 Trial of its Next ... - BioSpace

Sep 12, 2023 Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand …See details»

linkstock.net © 2022. All rights reserved